欧洲瘤学生物类似药与原始药的比较安全概况:对EudraVigilance数据库的分析
Victoria Nikitina1, Greta Santi Laurini1, Nicola Montanaro2
1Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Cancers
|July 29, 2023
概括
在瘤学中,生物相似单克隆抗体显示出与它们的参考生物相匹配的安全性. 营销后监测证实生物仿制药是安全有效的替代品,改善了患者获得癌症治疗的机会.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 生物技术是生物技术.
背景情况:
- 生物学家已经彻底改变了癌症护理,但高成本限制了获取.
- 生物类药物为原始生物制品提供了具有成本效益的替代品.
- 通过药物监督确保生物类似药物的安全性至关重要.
研究的目的:
- 分析和比较生物类似单克隆抗体在瘤学中的营销后药监数据.
- 评估生物仿制药的安全性,与它们的参考产品进行比较.
主要方法:
- 从EudraVigilance.com获取了为期两年的 (2021-2022) 药监数据.
- 使用报告几率比率进行了描述性和比较分析.
- 评估了bevacizumab,rituximab和trastuzumab生物类似药及其参考产品.
主要成果:
- 大多数报告的生物仿制药不良反应 (ADR) 不严重.
- 生物类药物的ADR概况与参考产品的ADR概况一致.
- 与原始药物相比,生物类似药没有发现任何重大安全问题.
结论:
- 生物类似药在瘤学中与参考生物药物具有安全等价性.
- 药监数据支持使用生物类似药作为有效的替代品.
- 生物类似药可以提高患者获得必要的癌症治疗的机会.
相关概念视频
Pharmacovigilance
891
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
891
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Comparing the Survival Analysis of Two or More Groups
224
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
224
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Hazard Ratio
159
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
159


